An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
Open accessThe DOI matches its Crossref record; 152 of the 155 references it cites were found in a registry or an index.
Abstract
Metabolic diseases, particularly diabetes mellitus (DM), are significant global public health concerns. Despite the widespread use of standard-of-care therapies, cardiovascular disease (CVD) remains the leading cause of death among diabetic patients. Early and evidence-based interventions to reduce CVD are urgently needed. Large clinical trials have recently shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) ameliorate adverse cardiorenal outcomes in patients with type 2 DM. These quite unexpected positive results represent a paradigm shift in type 2 DM management, from the sole importance of glycemic control to the simultaneous improvement of cardiovascular outcomes. Moreover, SGLT2i is also found to be cardio- and nephroprotective in non-diabetic patients. Several mechanisms, which may be potentially independent or at least separate from the reduction in blood glucose levels, have already been identified behind the beneficial effect of these drugs. However, there is still much to be understood regarding the exact pathomechanisms. This review provides an overview of the current literature and sheds light on the modes of action of novel antidiabetic drugs, focusing on inflammation, oxidative stress, and fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High-sensitivity C-reactive protein (hs-CRP), an indicator of systemic inflammation, was significantly reduced in people with T2D and cardiovascular disease treated with semaglutide.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [28]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 8×
“NF-κB and MCP-1 expression was attenuated with liraglutide treatment in hypertensive mice [70].”
BackgroundInfluentialRetractedAroor, A. R., Habibi, J., Kandikattu, H. K., Garro-Kacher, M. O., Barron, B. J., Chen, D., Hayden, M. R., Whaley‐Connell, A. T., Bender, S. B., Klein, T., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0544-4 · Cited by 76
Retracted2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Numerous CVOTs have shown the safety of GLP-1RA and the reduction in adverse cardiorenal outcomes in patients with T2DM [17,19,74].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Despite these gold-standard therapies reducing microvascular complications, the risk of CVD remains high, even in optimally managed patients [7,8].”
BackgroundOxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0039 · Cited by 2,232
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Cardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“GLP1RA can be categorized as short-acting compounds, which provide short-lived receptor activation (exenatide and lixisenatide), or as long-acting compounds (albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously [13].”
BackgroundType 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., Deanfield, J., Smeeth, L., Timmis, A., & Hemingway, H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70219-0 · Cited by 1,225
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease
Fan, D., Takawale, A., Lee, J., & Kassiri, Z. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-15 · Cited by 814
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Verma, S., Mazer, C. D., Yan, A. T., Mason, T., Garg, V., Teoh, H., Zuo, F., Quan, A., Farkouh, M. E., Fitchett, D. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042375 · Cited by 572
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · cited 1×
“Similar effects were observed in LDLr−/− mice, where both liraglutide and semaglutide attenuated systemic inflammation and plaque lesion development [69].”
ResultCardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464 · cited 1×
“Despite these gold-standard therapies reducing microvascular complications, the risk of CVD remains high, even in optimally managed patients [7,8].”
BackgroundWong, T. C., Piehler, K. M., Kang, I. A., Kadakkal, A., Kellman, P., Schwartzman, D. S., Mulukutla, S. R., Simon, M. A., Shroff, S. G., Kuller, L. H., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht193 · Cited by 379
Shah, Z., Kampfrath, T., Deiuliis, J. A., Zhong, J., Pineda, C., Ying, Z., Xu, X., Lu, B., Moffatt-Bruce, S., Durairaj, R., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.041418 · Cited by 377
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling
Frieler, R. A., & Mortensen, R. M. (2015) · Circulation · doi:10.1161/circulationaha.114.008788 · Cited by 334
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Li, J. H., Huang, X. R., Zhu, H., Oldfield, M., Cooper, M., Truong, L. D., Johnson, R. J., & Lan, H. Y. (2004) · The FASEB Journal · doi:10.1096/fj.02-1117fje · Cited by 264
Type 2 Diabetes and Hypertension: A Study on Bidirectional Causality
Sun, D., Zhou, T., Heianza, Y., Li, X., Fan, M., Fonseca, V. A., & Qi, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.314487 · Cited by 252
Shigiyama, F., Kumashiro, N., Miyagi, M., Ikehara, K., Kanda, E., Uchino, H., & Hirose, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0564-0 · Cited by 249
Brown, A. J. M., Gandy, S., McCrimmon, R., Houston, J. G., Struthers, A. D., & Lang, C. C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa419 · Cited by 239
Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa256 · Cited by 223 · cited 1×
“Additionally, liraglutide attenuated cardiometabolic dysregulation and reduced cardiac hypertrophy, myocardial fibrosis, and natriuretic peptide levels in a novel C57BL/6J mice model of heart failure with preserved ejection fraction (HFpEF) [140].”
BackgroundTian, J., Zhang, M., Suo, M., Liu, D., Wang, X., Liu, M., Pan, J., Jin, T., & An, F. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16601 · Cited by 212
(2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000178 · Cited by 211
Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage
Liu, Q., Wang, S., & Cai, L. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12250 · Cited by 206
The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience
Hiatt, W. R., Kaul, S., & Smith, R. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1309610 · Cited by 204
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Ghanim, H., Abuaysheh, S., Hejna, J., Green, K., Batra, M., Makdissi, A., Chaudhuri, A., & Dandona, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa057 · Cited by 197
Ferreira, L., Teixeira-de-Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R., Garrido, P., Sereno, J., Fernandes, R., et al. (2010) · Mediators of Inflammation · doi:10.1155/2010/592760 · Cited by 193
Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J. (2020) · Diabetes · doi:10.2337/db19-0991 · Cited by 193
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186 · cited 1×
“It also induced AMPK activation, via increasing calmodulindependent protein kinase-β activation, in human aortic endothelial cells [61].”
BackgroundMaier, H. J., Schips, T. G., Wietelmann, A., Krüger, M., Brunner, C., Sauter, M., Klingel, K., Böttger, T., Braun, T., & Wirth, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116584109 · Cited by 172
Leng, W., Ouyang, X., Lei, X., Wu, M., Chen, L., Wu, Q., Deng, W., & Liang, Z. (2016) · Mediators of Inflammation · doi:10.1155/2016/6305735 · Cited by 172
Abdollahi, E., Keyhanfar, F., Delbandi, A., Falak, R., Hajimiresmaiel, S. J., & Shafiei, M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174715 · Cited by 168
Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.08.033 · Cited by 166
Nath, S., Ghosh, S. K., & Choudhury, Y. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.10.007 · Cited by 164
Role of Oxidative Stress in Diabetic Cardiomyopathy
De Geest, B., & Mishra, M. (2022) · Antioxidants · doi:10.3390/antiox11040784 · Cited by 160
Tuleta, I., & Frangogiannis, N. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113904 · Cited by 150
Lee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J. (2021) · Journal of Immunology Research · doi:10.1155/2021/9944880 · Cited by 139 · cited 1×
“Empagliflozin reduced the expression of proinflammatory cytokine and chemokine release through the IKK/NF-κB/JAK2-STAT1/3, and MKK4/7-JNK pathways [38].”
BackgroundDai, Y., Mehta, J. L., & Chen, M. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6463-z · Cited by 123
Apaijai, N., Pintana, H., Chattipakorn, S. C., & Chattipakorn, N. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12176 · Cited by 119
Penna, C. R. R., Andreadou, I., Aragno, M., Beauloye, C., Bertrand, L., Lazou, A., Falcão‐Pires, I., Bell, R., Zuurbier, C. J., Pagliaro, P., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14993 · Cited by 114
Mahmoud, A. M., Al‐Rasheed, N. M., Hasan, I. H., Alamin, M. A., Al‐Ajmi, H. N., & Al-Rasheed, N. M. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s109287 · Cited by 113
Uthman, L., Li, X., Baartscheer, A., Schumacher, C. A., Baumgart, P., Hermanides, J., Preckel, B., Hollmann, M. W., Coronel, R., Zuurbier, C. J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112515 · Cited by 111
Ma, Z., Dai, J., Zhang, W., Yuan, Y., Liao, H., Zhang, N., Bian, Z., & Tang, Q. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13449 · Cited by 110
Aroor, A. R., Sowers, J. R., Bender, S. B., Nistala, R., Garro, M., Mugerfeld, I., Hayden, M. R., Johnson, M. S., Salam, M., Whaley-Connell, A., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1096 · Cited by 104
Monji, A., Mitsui, T., Bando, Y. K., Aoyama, M., Shigeta, T., & Murohara, T. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00990.2012 · Cited by 104
Inoue, T., Inoguchi, T., Sonoda, N., Hendarto, H., Makimura, H., Sasaki, S., Yokomizo, H., Fujimura, Y., Miura, D., & Takayanagi, R. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.03.026 · Cited by 103
Matsui, T., Nishino, Y., Takeuchi, M., & Yamagishi, S. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.02.003 · Cited by 103
Yu, Y.-W., Que, J.-Q., Liu, S., Huang, K.-Y., Qian, L., Weng, Y.-B., Rong, F.-N., Wang, L., Zhou, Y.-Y., Xue, Y.-J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.768214 · Cited by 103
Picatoste, B., Ramírez, E., Caro-Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078330 · Cited by 101
Bostick, B., Habibi, J., Ma, L., Aroor, A. R., Rehmer, N., Hayden, M. R., & Sowers, J. R. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.002 · Cited by 99
Eid, R. A., Bin-Meferij, M. M., El-kott, A. F., Eleawa, S. M., Zaki, M. S. A., Al-Shraim, M. M., El-Sayed, F., Eldeen, M. A., Alkhateeb, M. A., Alharbi, S., et al. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09984-5 · Cited by 97
Tate, M., Robinson, E., Green, B. D., McDermott, B. J., & Grieve, D. J. (2016) · Basic Research in Cardiology · doi:10.1007/s00395-015-0518-1 · Cited by 96
Wu, L., Wang, K., Wang, W., Wen, Z., Wang, P., Liu, L., & Wang, D. W. (2018) · Aging Cell · doi:10.1111/acel.12763 · Cited by 92
Chen, S., Wang, Q., Christodoulou, A., Mylonas, N., Bakker, D., Nederlof, R., Hollmann, M. W., Weber, N. C., Coronel, R., Wakker, V., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061688 · Cited by 92
Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway
Wei, H., Bu, R., Yang, Q., Jia, J., Li, T., Wang, Q., & Chen, Y. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8905917 · Cited by 91 · cited 1×
“In a high-fat diet T2DM mice model, exendin4 protected against heart remodeling and attenuated the levels of IL-1β, IL-6, TNF-α, ICAM-1, and VCAM-1 by inhibiting NLRP3 inflammasome-dependent inflammatory pathways [66,67].”
BackgroundNakatsu, Y., Kokubo, H., Bumdelger, B., Yoshizumi, M., Yamamotoya, T., Matsunaga, Y., Ueda, K., Inoue, Y., Inoue, M.-K., Fujishiro, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081704 · Cited by 89
Effects of DPP-4 inhibition on cardiac metabolism and function in mice
Lenski, M., Kazakov, A., Marx, N., Böhm, M., & Laufs, U. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.08.001 · Cited by 88
Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Sezai, A., Sekino, H., Unosawa, S., Taoka, M., Osaka, S., & Tanaka, M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0877-2 · Cited by 88
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Nuamnaichati, N., Mangmool, S., Chattipakorn, N., & Parichatikanond, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00805 · Cited by 81
Zhang, X., Zhang, Z., Zhao, Y., Jiang, N., Qiu, J., Yang, Y., Li, J., Liang, X., Wang, X., Tse, G., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005945 · Cited by 78
Uthman, L., Kuschma, M. C., Römer, G., Boomsma, M., Keßler, J., Hermanides, J., Hollmann, M. W., Preckel, B., Zuurbier, C. J., & Weber, N. C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07083-w · Cited by 77
Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation
Luo, X., Hu, Y., He, S., Ye, Q., Lv, Z., Liu, J., & Chen, X. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.07.008 · Cited by 74
Zhang, L., Tian, J., Diao, S., Zhang, G., Xiao, M., & Chang, D. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109252 · Cited by 73
Croteau, D., Luptak, I., Chambers, J. M., Hobai, I., Panagia, M., Pimentel, D. R., Siwik, D. A., Qin, F., & Colucci, W. S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019995 · Cited by 73
Faridvand, Y., Kazemzadeh, H., Vahedian, V., Mirzajanzadeh, P., Nejabati, H. R., Safaie, N., Maroufi, N. F., Pezeshkian, M., Nouri, M., & Jodati, A. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13638 · Cited by 73
Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
Hattori, S. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0395-5 · Cited by 72
Birnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 72
Lee, D., Lee, E.-S., Alam, M. M., Jang, J.-H., Lee, H.-S., Oh, H., Kim, Y., Manzoor, Z., Koh, Y., Kang, D.-G., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.10.002 · Cited by 70
Nikolaou, P., Mylonas, N., Makridakis, M., Makrecka‐Kuka, M., Iliou, A., Zerikiotis, S., Efentakis, P., Kampoukos, S., Kostomitsopoulos, N. G., Vilšķe̅rsts, R., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00934-7 · Cited by 70
Connelly, K. A., Zhang, Y., Advani, A., Advani, S. L., Thai, K., Yuen, D. A., & Gilbert, R. E. (2013) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12005 · Cited by 67
Kanbay, M., Tapoi, L. C., Ureche, C., Tanrıöver, C., Çevik, E., Demiray, A., Afşar, B., Cherney, D. Z. I., & Covic, A. C. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02943-2 · Cited by 67
Zhang, X., Zhang, Z., Yang, Y., Suo, Y., Liu, R., Qiu, J., Zhao, Y., Jiang, N., Liu, C., Tse, G., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0803-z · Cited by 65
Wang, J., Huang, X., Liu, H., Chen, Y., Li, P., Liu, L., Li, J., Ren, Y., Huang, J., Xiong, E., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1122494 · Cited by 65
Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
Rahadian, A., Fukuda, D., Salim, H. M., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., & Sata, M. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.52100 · Cited by 63
Feijóo‐Bandín, S., Aragón‐Herrera, A., Otero-Santiago, M., Anido‐Varela, L., Moraña‐Fernández, S., Tarazón, E., Roselló‐Lletí, E., Portolés, M., Gualillo, O., González‐Juanatey, J. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105634 · Cited by 63
Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation
Zhou, Y., He, X., Chen, Y., Huang, Y., Wu, L., & He, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.179 · Cited by 61
Yu, W., Zha, W., & Ren, J. T. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5396806 · Cited by 61
Tanaka, A., Shimabukuro, M., Machii, N., Teragawa, H., Okada, Y., Shima, K. R., Takamura, T., Taguchi, I., Hisauchi, I., Toyoda, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-1177 · Cited by 60
Cherney, D. Z. I., Repetto, E., Wheeler, D. C., Arnold, S. V., MacLachlan, S., Hunt, P. R., Chen, H., Vora, J., & Kosiborod, M. (2020) · American Journal of Nephrology · doi:10.1159/000504558 · Cited by 60
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Kolesnik, E., Scherr, D., Rohrer, U., Benedikt, M., Manninger, M., Sourij, H., & von Lewinski, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031678 · Cited by 60
de Boer, S. A., Heerspink, H. J. L., Juárez‐Orozco, L. E., van Roon, A. M., Kamphuisen, P. W., Smit, A. J., Slart, R. H. J. A., Lefrandt, J. D., & Mulder, D. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12925 · Cited by 59
Trang, N. N., Chung, C., Lee, T., Cheng, W., Kao, Y., Huang, S.-Y., Lee, T.-I., & Chen, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031177 · Cited by 59
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
de Mortanges, A. P., Salvador, D., Laimer, M. W., Muka, T., Wilhelm, M., & Bano, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751214 · Cited by 55
Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Wiciński, M., Górski, K. M., Wódkiewicz, E., Walczak, M., Nowaczewska, M., & Malinowski, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072275 · Cited by 53
Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52
AGE-RAGE signal generates a specific NF-κB RelA “barcode” that directs collagen I expression
Peng, Y., Kim, J.-M., Park, H.-S., Yang, A., Islam, C., Lakatta, E. G., & Lin, L. (2016) · Scientific Reports · doi:10.1038/srep18822 · Cited by 51
Ding, W., Chang, W.-G., Guo, X.-C., Liu, Y., Xiao, D.-D., Ding, D., Wang, J.-X., & Zhang, X.-J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00202 · Cited by 50
Gaspari, T., Brdar, M., Lee, H. W., Spizzo, I., Hu, Y., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115605000 · Cited by 49
Jensen, J. K., Zobel, E. H., von Scholten, B. J., Rotbain Curovic, V., Hansen, T. W., Rossing, P., Kjaer, A., & Ripa, R. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.790405 · Cited by 47
Hu, J., Xu, J., Tan, X., Li, D., Yao, D., Xu, B., & Lei, Y. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02409-5 · Cited by 42
Jax, T. W., Stirban, A. O., Terjung, A., Esmaeili, H. A., Berk, A., Thiemann, S., CHILTON, R. J., von Eynatten, M., & Marx, N. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0493-3 · Cited by 40
Li, F.-F., Gao, G., Li, Q., Zhu, H., Su, X., Wu, J.-D., Ye, L., & Ma, J. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5347262 · Cited by 39
Daousi, C., Pinkney, J. H., Cleator, J., Wilding, J. P. H., & Ranganath, L. R. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.03.004 · Cited by 38
Liu, Y., Huang, Z., Wang, L., Liu, X., Wang, Y.-M., Zhang, Y., & Zhang, M. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.12.007 · Cited by 38
Hodrea, J., Saeed, A., Molnár, Á., Fintha, A., Bárczi, A., Wagner, L. J., Szabo, A. J., Fekete, A., & Balogh, D. B. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263285 · Cited by 38
Self-citationQian, P., Tian, H., Wang, Y., Lu, W., Li, Y., Ma, T., Gao, X., & Yao, W. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114209 · Cited by 36
Hong, S.-K., Choo, E. H., Ihm, S., Chang, K., & Seung, K. (2017) · Metabolism · doi:10.1016/j.metabol.2017.07.007 · Cited by 35
Qi, Y., Du, X., Yao, X., & Zhao, Y. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1578783 · Cited by 35
Moon, J.-Y., Woo, J. S., Seo, J.-W., Lee, A., Kim, D. J., Kim, Y., Kim, S.-Y., Lee, K. H., Lim, S., Cheng, X. W., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150745 · Cited by 34
Bugga, P., Mohammed, S. A., Alam, M. J., Katare, P. B., Meghwani, H., Maulik, S. K., Arava, S. K., & Banerjee, S. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120862 · Cited by 33
Pignatelli, P., Baratta, F., Buzzetti, R., D’Amico, A., Castellani, V., Bartimoccia, S., Siena, A., D’Onofrio, L., Maddaloni, E., Pingitore, A., et al. (2022) · Antioxidants · doi:10.3390/antiox11101878 · Cited by 33
Younis, A., Eskenazi, D., Goldkorn, R., Leor, J., Naftali-Shani, N., Fisman, E. Z., Tenenbaum, A., Goldenberg, I., & Klempfner, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0551-5 · Cited by 32
Zhang, Z., Wang, X., Yang, L., Yang, L., & Ma, H. (2021) · PubMed Central · doi:10.22038/ijbms.2021.56771.12677 · Cited by 30
Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models
Fu, Z., Mui, D., Zhu, H., & Zhang, Y. (2020) · Aging · doi:10.18632/aging.103181 · Cited by 29
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Chan, J. C. H., & Chan, M. C. Y. (2023) · Medicina · doi:10.3390/medicina59020388 · Cited by 28
Koshibu, M., Mori, Y., Saito, T., Kushima, H., Hiromura, M., Terasaki, M., Takada, M., Fukui, T., & Hirano, T. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00511.2018 · Cited by 27
Navabi, R., Negahdari, B., Hajizadeh‐Saffar, E., Hajinasrollah, M., Jenab, Y., Rabbani, S., Pakzad, M., Hassani, S., Hezavehei, M., Atrabi, M. J., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119374 · Cited by 27
Younce, C. W., Niu, J., Ayala, J., Burmeister, M. A., Smith, L. H., Kolattukudy, P. E., & Ayala, J. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.08.022 · Cited by 26
Wang, X., Zhang, F., Yang, F., Ding, Z., Agarwal, N., Guo, Z., & Mehta, J. L. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.72 · Cited by 26
Baylan, U., Korn, A., Emmens, R. W., Schalkwijk, C. G., Niessen, H. W. M., Krijnen, P. A. J., & Şimşek, S. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13807 · Cited by 26
Zhao, S.-M. (2017) · The Chinese Journal of Physiology · doi:10.4077/cjp.2017.baf434 · Cited by 25
Brown, S. M., Smith, C., Meuth, A. I., Khan, M., Aroor, A. R., Cleeton, H. M., Meininger, G. A., Sowers, J. R., DeMarco, V. G., Chandrasekar, B., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00416 · Cited by 23
Lin, C.-P., Huang, P., Chen, C., Wu, M., Chen, J.-S., Chen, J., & Lin, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-97361-w · Cited by 23
Li, H., Xu, X., Wang, J., Kong, X., Chen, M., Jing, T., Zhang, Z., Yin, G., Liu, X., Hu, Y., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/6423987 · Cited by 21
A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats
Nakajima, Y., Ito, S., Asakura, M., Min, K.-D., Fu, H. Y., Imazu, M., Hitsumoto, T., Takahama, H., Shindo, K., Fukuda, H., et al. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.03.009 · Cited by 18
Li, X., Kerindongo, R. P., Preckel, B., Kalina, J.-O., Hollmann, M. W., Zuurbier, C. J., & Weber, N. C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114228 · Cited by 17
Sun, Y., Yan, D., Hao, Z., Cui, L., & Li, G. (2020) · Medical Science Monitor · doi:10.12659/msm.921891 · Cited by 16
Saxagliptin protects against hypoxia-induced damage in H9c2 cells
Zhang, L., Qi, X., Zhang, G., Zhang, Y., & Tian, J. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108864 · Cited by 15
Cai, H., Zhou, L., Liu, J., Li, Z., & Chen, S. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.018 · Cited by 15
Gu, Y., Ct, M., Hl, G., Shi, L., Xt, T., & Xu, W. Q. (2018) · PubMed · doi:10.26355/eurrev_201812_16668 · Cited by 14
Meng, J., Zhang, W., Wang, C., Xiong, S., Wang, Q., Li, H., Liu, G., & Hao, Z. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106996 · Cited by 14
Tanajak, P., Sa‐nguanmoo, P., Apaijai, N., Wang, X., Liang, G., Li, X., Jiang, C., Chattipakorn, S. C., & Chattipakorn, N. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12263 · Cited by 13
Cessario, J., Pierre-Louis, V., Wahl, J., & Li, Z. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00224-4 · Cited by 13
Ma, G., Liu, Y., Wang, Y., Wen, Z., Li, X., Zhai, H., Li, M., & Luo, J. (2020) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2020.1719517 · Cited by 12
Osaka, N., Mori, Y., Terasaki, M., Hiromura, M., Saito, T., Yashima, H., Shiraga, Y., Kawakami, R., Ohara, M., Fukui, T., et al. (2022) · Journal of International Medical Research · doi:10.1177/03000605221097490 · Cited by 12
Picatoste, B., RamÃrez, E., Caro‐Vadillo, A., Iborra, C., Egido, J., n, J. T., & Lorenzo, Ó. (2013) · PLoS ONE · doi:10.1371/annotation/df98874f-c1bd-4a13-b474-942fbb956287 · Cited by 9
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
Teragawa, H., Morimoto, T., Fujii, Y., Ueda, T., Sakuma, M., Shimabukuro, M., Arasaki, O., Node, K., Nomiyama, T., & Ueda, S. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s282968 · Cited by 7
Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome
Panda, S. P. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220531123116 · Cited by 6
[Effects of Sitagliptin on myocardial remodeling and autophagy in diabetic mice and its mechanism].
Chen, Y., Zhang, L., Liu, Q., & Li, X. (2021) · PubMed · doi:10.12047/j.cjap.6129.2021.073 · Cited by 3
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
RYKOVA, E. Y., Klimontov, V. V., Shmakova, E. O., Korbut, A. I., Merkulova, T. I., & Kzhyshkowska, J. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041670 · Cited by 100
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
“Strong evidence has shown the anti-in fl ammatory effect of GLP-1RA (16, 17).”
BackgroundInfluentialMethylglyoxal Formation—Metabolic Routes and Consequences
Vašková, J., Sabolová, G., Pudelský, J., Palenčár, D., & Mičková, H. (2025) · Antioxidants · doi:10.3390/antiox14020212 · Cited by 71
Nuñez-Selles, A. J., Nuñez-Musa, R. A., & Guillen-Marmolejos, R. A. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1611842 · Cited by 51
Metadata
- Authors
- Balogh, D. B., Wagner, L. J., & Fekete, A.
- Affiliations
- Semmelweis University (HU)
- Corresponding author
- Fekete, Andrea
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-04-24
- Volume
- 24
- Issue
- 9
- Pages
- 7789
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10177821
- OpenAlex
- W4366989020
- Cited by
- 38
- References
- 155
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 8 · 2023: 3
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- New National Excellence Program of The Ministry for Culture and Innovation (UNKP-22-4-II-SE-2, TKP2021-EGA-24)
- Ministry of Innovation and Technology of Hungary (UNKP-22-4-II-SE-2, TKP2021-EGA-24)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- cardioprotection, type 2 diabetes, cardiovascular disease, SGLT2 inhibitors, GLP-1 receptor agonists, inflammation, oxidative stress, myocardial fibrosis, cardiorenal outcomes, drug mechanisms of action
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Fibrosis, Humans, Hypoglycemic Agents, Inflammation, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.